BIND Therapeutics prices IPO at $15, within the range

By
A A A

BIND Therapeutics, a biotech developing targeting mechanisms to enhance existing therapeutics, raised $71 million by offering 4.7 million shares at $15, within the range of $14 to $16. BIND Therapeutics plans to list on the NASDAQ under the symbol BIND. BIND Therapeutics initially filed confidentially on 6/28/2013. Credit Suisse and Cowen & Company acted as lead managers on the deal.



The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.



This article appears in: News Headlines , IPOs

Referenced Stocks: BIND

Renaissance Capital

Renaissance Capital

More from Renaissance Capital:

Related Videos

Cheap Ways to Sleep Better
Cheap Ways to Sleep Better          

Stocks

Referenced

100%

Most Active by Volume

105,679,298
  • $16.13 ▼ 0.19%
43,130,824
  • $101.32 ▲ 0.74%
24,108,289
  • $59.80 ▲ 7.34%
22,524,427
  • $26.15 ▼ 1.06%
22,194,114
  • $24.65 ▼ 0.96%
21,835,360
  • $99.05 ▲ 0.15%
20,872,575
  • $34.94 ▼ 0.60%
20,561,803
    $74.57 unch
As of 8/22/2014, 04:02 PM

Find a Credit Card

Select a credit card product by:
Select an offer:
Search
Data Provided by BankRate.com